Table 3 Outcomes within 30 days of receiving tocilizumab

Clinical improvement

36/60 (60.0)

13/36 (36.1%)

23/36 (63.9%)

0.0015

 WHO ordinal scale on day of tocilizumab administration, median (range)

4 (3–7)

4 (4–7)

4 (3–7)

0.47

 WHO ordinal scale on day 30, median (range)

1 (1–4)

1 (1–4)

1 (1–4)

 -

Mortality

9/60 (15.0)

5/9 (55.6%)

4/9 (44.4%)

1.00

 Time to death from receiving tocilizumab, median days (range)

6 (1–14)

Discharged alive

33/60 (55.0)

15/33 (45.5%)

18/33 (54.5%)

0.27

 Hospital length of stay, median days (range)

15 (0–32)

Required ICU care

52/60 (86.7)

31/52 (59.6%)

21/52 (40.4%)

0.02

 Remained admitted to ICU at day 30

13/52 (25.0)

 Step down to floor at day 30

5/52 (9.6)

 Discharged from hospital alive by day 30

25/52 (48.1)

 Died by day 30

9/52 (17.3)

Required invasive mechanical ventilation

29/60 (48.3)

19/29 (65.5%)

10/29 (34.5%)

0.12

Successful extubation

13/29 (44.8)

7/13 (53.8%)

6/13 (46.2%)

0.27

 Duration of mechanical ventilation, median days (range)

15 (6–35)

Infectious complications

16/60 (26.7)

10/16 (62.5%)

6/16 (37.5%)

0.57

 Time to first infection, median days (range)

10.5 (2–28)

 Cultures drawn while in ICU, n (%)

26/29 (89.7)

 Cultures drawn while intubated, n (%)

25/29 (86.2)

  Respiratory

14/29 (48.3)

  Bloodstream

14/29 (48.3)

  Urinary

1/29 (3.4)